Ethical Issues in Drug Testing, Approval and Pricing: The Clot-Dissolving Drugs

&
Hastings Center Report 26 (1):42 (1996)
  Copy   BIBTEX

Abstract

Book reviewed in this article: Ethical Issues in Drug Testing, Approval and Pricing: The Clot‐Dissolving Drugs. By Baruch Brody.

Categories

Keywords

Reprint years

2012

DOI

10.2307/3527531

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,682

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Ethical Issues in Drug Testing, Approval and Pricing: the Clot-Dissolving Drugs by Baruch A. Brody.U. Schueklenk - 1998 - Bioethics 12:79-81.
Ethical Issues in Drug Testing, Approval and Pricing: The Clot-Dissolving Drugs.Baruch A. Brody & Udo Schuklenk - 1998 - Bioethics 12 (1):79-81.
Ethical Issues in Drug Testing, Approval and Pricing: The Clot-Dissolving Drugs.John Lantos - 1997 - Perspectives in Biology and Medicine 40 (3):455.
Ethical Issues in New Drug Prescribing.Lindsay W. Cole, Jennifer C. Kesselheim & Aaron S. Kesselheim - 2012 - Journal of Bioethical Inquiry 9 (1):77-83.
An analysis of common ethical justifications for compassionate use programs for experimental drugs.Kasper Raus - 2016 - BMC Medical Ethics 17 (1):60.
Pharmacogenetics: Ethical issues and policy options.Allen E. Buchanan, Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John A. Robertson & Baruch A. Brody - 2002 - Kennedy Institute of Ethics Journal 12 (1):1-15.
Delaying approval of a critical drug: Safety, efficacy, economics, compassion. [REVIEW]Leo T. Rosenberg - 1994 - Journal of Medical Humanities 15 (4):243-250.
The approval of over-the-counter HIV tests: Playing fair when making the rules. [REVIEW]Melissa Whellams - 2008 - Journal of Business Ethics 77 (1):5 - 15.
Five Un‐Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
The Approval of Over-the-Counter HIV Tests: Playing Fair When Making the Rules.Melissa Whellams - 2008 - Journal of Business Ethics 77 (1):5-15.
Ethical considerations in the testing of biopharmaceuticals for adventitious agents.Richard S. Woodward - 1995 - Science and Engineering Ethics 1 (3):273-282.
No Harm, No Foul? Justifying Bans On Safe Performance-Enhancing Drugs.John Gleaves - 2010 - Sport, Ethics and Philosophy 4 (3):269-283.
Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry? [REVIEW]Thomas A. Hemphill - 2010 - Journal of Business Ethics 94 (2):225 - 242.
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (phase III) clinical trials are major obstacles to advances in health care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.
Judgments of the fairness of using performance enhancing drugs.John Sabini & John Monterosso - 2005 - Ethics and Behavior 15 (1):81 – 94.

Analytics

Added to PP
2018-04-09

Downloads
7 (#1,403,593)

6 months
4 (#843,989)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references